Year: 2026
Type: article
Abstract: A complicated interaction of pharmacokinetic (PK), pharmacodynamic (PD), genetic, and epigenetic factors influences inter-individual variability in response to selective serotonin reuptake inhibitors (SSRIs). This review summarizes recent findings in antidepressant pharmacogenetics, emphasizing the functions of important pharmacodynamic loci (SLC6A4, HTR2A, BDNF, ABCB1) and metabolic genes (CYP2C19, CYP2D6) in regulating drug exposure, efficacy, and tolerability. Evidence from observational studies and previous reports suggests that pharmacogenomic-guided therapy may improve treatment outcomes, especially for individuals with abnormal metabolic profiles or treatment resistance. Major obstacles to clinical translation include small effect sizes, population-specific heterogeneity, retrospective studies, and uneven integration with therapeutic drug monitoring. Additional implementation barriers include workflow integration, patient access, cost, and clinical education. To optimize the clinical impact of precision psychiatry, future research should focus on prospective, multicenter trials with diverse populations, standardized clinical decision frameworks, and integration of polygenic, epigenetic, and environmental data. This review investigates whether integrating pharmacogenomic information into SSRI prescribing can enhance treatment outcomes and reduce adverse events.
Source: Pittsburgh Undergraduate Review
DOI: 10.5195/pur.2026.192
Author: Aadi Balsaraf
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Keywords: pharmacogenetics, selective serotonin reuptake inhibitors, antidepressants, personalized medicine, serotonin transporter, HTR2A, brain-derived neurotrophic factor, P-glycoprotein, CYP2C19, CYP2D6, drug metabolism, treatment resistance, therapeutic drug monitoring, precision psychiatry, epigenetics, polygenic risk
Open Access status: diamond
OpenAlex ID: W7234414564
